Search research articles
Contact Us
Filters
Showing results (1-10 of 188) with videos related to
Page
of 19
Sort By:
Current HIV Research
|
August 6, 2016
HIV Infection and Myocardial Infarction
Leonardo Calza
HIV Clinical Trials
|
August 2, 2012
Renal toxicity associated with antiretroviral therapy
Leonardo Calza
Drug, Healthcare and Patient Safety
|
June 25, 2011
Long-term use of rosuvastatin: a critical risk benefit appraisal and comparison with other antihyperlipidemics
Leonardo Calza
Recenti Progressi in Medicina
|
February 28, 2006
["Mad cow" disease: scientific novelty or academic terrorism?]
Roberto Manfredi, Leonardo Calza
AIDS Patient Care and Stds
|
February 23, 2008
Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients
Roberto Manfredi, Leonardo Calza
AIDS (London, England)
|
November 7, 2006
Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex, and a baseline CD4 cell count greater than 250 cells/microl
Roberto Manfredi, Leonardo Calza
Current HIV Research
|
September 29, 2012
Protease inhibitor monotherapy as maintenance regimen in patients with HIV infection
Leonardo Calza, Roberto Manfredi
Le Infezioni in Medicina
|
April 22, 2003
[HIV genotypic mutation selectively induced by the protease inhibitor nelfinavir at codon 30. Case series and consequences for antiretroviral management]
Roberto Manfredi, Leonardo Calza
Recenti Progressi in Medicina
|
December 2, 2008
[Two novel fixed formulations of nucleoside analogues (tenofovir-emtricitabine, and abacavir-lamivudine). Prospective, open study on clinical practice and therapeutic perspectives, in patients naïve and in subjects pre-treated with antiretrovirals]
Roberto Manfredi, Leonardo Calza
Recenti Progressi in Medicina
|
February 25, 2010
[Malignancies not included among AIDS-defining disorders, in the era of highly active antiretroviral therapy]
Roberto Manfredi, Leonardo Calza
Page
of 19
Search research articles
Search
Showing results (1-10 of 188) with videos related to
Sort By:
Page
of 19
Current HIV Research
|
August 6, 2016
HIV Infection and Myocardial Infarction
Leonardo Calza
HIV Clinical Trials
|
August 2, 2012
Renal toxicity associated with antiretroviral therapy
Leonardo Calza
Drug, Healthcare and Patient Safety
|
June 25, 2011
Long-term use of rosuvastatin: a critical risk benefit appraisal and comparison with other antihyperlipidemics
Leonardo Calza
Recenti Progressi in Medicina
|
February 28, 2006
["Mad cow" disease: scientific novelty or academic terrorism?]
Roberto Manfredi, Leonardo Calza
AIDS Patient Care and Stds
|
February 23, 2008
Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients
Roberto Manfredi, Leonardo Calza
AIDS (London, England)
|
November 7, 2006
Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex, and a baseline CD4 cell count greater than 250 cells/microl
Roberto Manfredi, Leonardo Calza
Current HIV Research
|
September 29, 2012
Protease inhibitor monotherapy as maintenance regimen in patients with HIV infection
Leonardo Calza, Roberto Manfredi
Le Infezioni in Medicina
|
April 22, 2003
[HIV genotypic mutation selectively induced by the protease inhibitor nelfinavir at codon 30. Case series and consequences for antiretroviral management]
Roberto Manfredi, Leonardo Calza
Recenti Progressi in Medicina
|
December 2, 2008
[Two novel fixed formulations of nucleoside analogues (tenofovir-emtricitabine, and abacavir-lamivudine). Prospective, open study on clinical practice and therapeutic perspectives, in patients naïve and in subjects pre-treated with antiretrovirals]
Roberto Manfredi, Leonardo Calza
Recenti Progressi in Medicina
|
February 25, 2010
[Malignancies not included among AIDS-defining disorders, in the era of highly active antiretroviral therapy]
Roberto Manfredi, Leonardo Calza
Page
of 19